AbCellera Biologics

ABCL

Market cap $1.28B

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Bruker Reach Global Settlement of Patent Litigation.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbCellera Biologics Inc. ( ABCL ) Jefferies London Healthcare Conference 2025 November 20, 2025 8:00 AM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Presentation Unknown Analyst Great.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Stephen Quake to its Board of Directors.

AbCellera Biologics Inc. ( ABCL ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Tryn Stimart - Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Carl L. Hansen - CEO, President & Chairperson Andrew Booth - Chief Financial Officer Conference Call Participants Malcolm Hoffman - BMO Capital Markets Equity Research Andrea Tan - Goldman Sachs Group, Inc., Research Division Joshua Nickerson - Stifel, Nicolaus & Company, Incorporated, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Jacqueline Kisa - TD Cowen, Research Division Presentation Operator Good afternoon, and welcome to AbCellera's Third Quarter 2025 Business Update Conference Call.

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.17 per share a year ago.

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2025 Business Results.